Literature DB >> 33429731

Xuan Fei Bai Du Fang for treating coronavirus disease 2019: A protocol for systematic review and meta-analysis.

Yuying Cui1,2, Jinming Yao2,3, Guoliang Shao4, Lin Liao2,3.   

Abstract

BACKGROUND: Coronavirus disease 2019 (COVID-19) is a respiratory infectious disease with a high fatality rate. Up to now, there are an estimated 26 million confirmed cases and 865,000 deaths around the world. But no effective way can control this disease. As the country that first discovered and treated the COVID-19, China has formed relatively mature prevention and treatment methods such as "3 prescriptions and 3 drugs." Xuan Fei Bai Du Fang, as a member of "3 prescriptions and 3 drugs," has very good clinical effects.
METHODS: The PubMed, EMBASE, ClinicalTrials.gov, Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases were searched for randomized controlled studies published to date. This study only screens clinical randomized controlled trials on QFBDF for COVID-19 to evaluate its efficacy and safety.Import all literatures that meet the requirements into Endnote X9 software. The information was finally cross-checked by 2 reviewers. Papers selected for review were assessed for risk of bias according to the criteria. Quality assessment on design of study, risk of bias, indirectness and imprecision were assessed using the GRADE framework. Where sufficient studies were available, publication bias was assessed visually using funnel plots. Relative risks for primary and secondary outcomes were calculated on an intent-to-treat basis and pooled using random effects meta-analysis. the continuous is expressed by mean difference or standard mean difference, eventually the data is synthesized using a fixed effect model or a random effect model depending on whether or not heterogeneity exists. The heterogeneity of studies will be evaluated by Q-test and I2 statistic with RevMan5.3.
RESULTS: The time from a positive diagnosis to a negative result of 2 consecutive nucleic acid tests (not on the same day), cure rate. The results of our research will be published in a peer-reviewed journal.
CONCLUSION: The purpose of this systematic review is to provide new evidence for the effectiveness and safety of Xuan Fei Bai Du Fang in the treatment of COVID-19. PROSPERO REGISTRATION NUMBER: CRD42020213950.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33429731      PMCID: PMC7793340          DOI: 10.1097/MD.0000000000023485

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  7 in total

1.  Chloroquine and COVID-19 - a potential game changer?

Authors:  Beattie Rh Sturrock; Timothy Jt Chevassut
Journal:  Clin Med (Lond)       Date:  2020-04-17       Impact factor: 2.659

2.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

3.  Effect of heat and humidity on the incidence and mortality due to COVID-19 pandemic in European countries.

Authors:  S A Meo; A A Abukhalaf; A A Alomar; O Y Sumaya; W Sami; K M Shafi; A S Meo; A M Usmani; J Akram
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-09       Impact factor: 3.507

4.  Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming.

Authors:  Jian Chen; Yong-Kui Wang; Yuan Gao; Ling-San Hu; Jiang-Wei Yang; Jian-Ru Wang; Wen-Jie Sun; Zhi-Qiang Liang; Ye-Min Cao; Yong-Bing Cao
Journal:  Biomed Pharmacother       Date:  2020-05-25       Impact factor: 6.529

Review 5.  Bioactive Ingredients in Chinese Herbal Medicines That Target Non-coding RNAs: Promising New Choices for Disease Treatment.

Authors:  Yan Dong; Hengwen Chen; Jialiang Gao; Yongmei Liu; Jun Li; Jie Wang
Journal:  Front Pharmacol       Date:  2019-05-21       Impact factor: 5.810

6.  Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.

Authors:  Ivan Fan-Ngai Hung; Kwok-Cheung Lung; Eugene Yuk-Keung Tso; Raymond Liu; Tom Wai-Hin Chung; Man-Yee Chu; Yuk-Yung Ng; Jenny Lo; Jacky Chan; Anthony Raymond Tam; Hoi-Ping Shum; Veronica Chan; Alan Ka-Lun Wu; Kit-Man Sin; Wai-Shing Leung; Wai-Lam Law; David Christopher Lung; Simon Sin; Pauline Yeung; Cyril Chik-Yan Yip; Ricky Ruiqi Zhang; Agnes Yim-Fong Fung; Erica Yuen-Wing Yan; Kit-Hang Leung; Jonathan Daniel Ip; Allen Wing-Ho Chu; Wan-Mui Chan; Anthony Chin-Ki Ng; Rodney Lee; Kitty Fung; Alwin Yeung; Tak-Chiu Wu; Johnny Wai-Man Chan; Wing-Wah Yan; Wai-Ming Chan; Jasper Fuk-Woo Chan; Albert Kwok-Wai Lie; Owen Tak-Yin Tsang; Vincent Chi-Chung Cheng; Tak-Lun Que; Chak-Sing Lau; Kwok-Hung Chan; Kelvin Kai-Wang To; Kwok-Yung Yuen
Journal:  Lancet       Date:  2020-05-10       Impact factor: 79.321

Review 7.  Combating COVID-19 with integrated traditional Chinese and Western medicine in China.

Authors:  Liqiang Ni; Lili Chen; Xia Huang; Chouping Han; Jianrong Xu; Hong Zhang; Xin Luan; Yongfang Zhao; Jianguang Xu; Weian Yuan; Hongzhuan Chen
Journal:  Acta Pharm Sin B       Date:  2020-06-27       Impact factor: 11.413

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.